StreetInsider.com News Articles

Form 4 KAZIA THERAPEUTICS LTD For: Jan 08 Filed by: Bonacorda Jeffrey

Wed, 08 Jul 2026 16:59:00 -0400

si-local-file:///var/storage/secattach/20260708/26748190.html

Form 4 KAZIA THERAPEUTICS LTD For: Jan 08 Filed by: Bonacorda Jeffrey

Wed, 08 Jul 2026 16:59:00 -0400

si-local-file:///var/storage/secattach/20260708/26748190.html

Form 4 KAZIA THERAPEUTICS LTD For: Jan 08 Filed by: Friend John E. II

Wed, 08 Jul 2026 16:59:00 -0400

si-local-file:///var/storage/secattach/20260708/26748193.html

Form 4 KAZIA THERAPEUTICS LTD For: Jan 08 Filed by: Friend John E. II

Wed, 08 Jul 2026 16:59:00 -0400

si-local-file:///var/storage/secattach/20260708/26748193.html

Form 4 KAZIA THERAPEUTICS LTD For: Jan 08 Filed by: Coffey Steven R. S.

Wed, 08 Jul 2026 16:59:00 -0400

si-local-file:///var/storage/secattach/20260708/26748197.html

Form 4 KAZIA THERAPEUTICS LTD For: Jan 08 Filed by: Coffey Steven R. S.

Wed, 08 Jul 2026 16:59:00 -0400

si-local-file:///var/storage/secattach/20260708/26748197.html

Form 4 KAZIA THERAPEUTICS LTD For: Jan 08 Filed by: Cain David

Wed, 08 Jul 2026 16:58:00 -0400

si-local-file:///var/storage/secattach/20260708/26748181.html

Form 4 KAZIA THERAPEUTICS LTD For: Jan 08 Filed by: Cain David

Wed, 08 Jul 2026 16:58:00 -0400

si-local-file:///var/storage/secattach/20260708/26748181.html

Form 4 KAZIA THERAPEUTICS LTD For: Jan 08 Filed by: Davidson Ebru

Wed, 08 Jul 2026 16:58:00 -0400

si-local-file:///var/storage/secattach/20260708/26748184.html

Form 4 KAZIA THERAPEUTICS LTD For: Jan 08 Filed by: Davidson Ebru

Wed, 08 Jul 2026 16:58:00 -0400

si-local-file:///var/storage/secattach/20260708/26748184.html

Form 4 KAZIA THERAPEUTICS LTD For: Jan 08 Filed by: APPLE ROBERT F

Wed, 08 Jul 2026 16:57:00 -0400

si-local-file:///var/storage/secattach/20260708/26748178.html

Form 4 KAZIA THERAPEUTICS LTD For: Jan 08 Filed by: APPLE ROBERT F

Wed, 08 Jul 2026 16:57:00 -0400

si-local-file:///var/storage/secattach/20260708/26748178.html

BTIG Starts Kazia Therapeutics (KZIA) at Buy

Wed, 01 Jul 2026 06:06:30 -0400

BTIG analyst Kambiz Yazdi initiates coverage on Kazia Therapeutics (NASDAQ: KZIA) with a Buy rating and a price target of $34.00.

The analyst comments "Kazia Therapeutics is a clinical-stage oncology company advancing paxalisib, an oral brain-penetrant dual PI3K/mTOR inhibitor in-licensed from Genentech in 2016, across TNBC, GBM, and pediatric brain cancers. The Company is also developing NDL2 (PD-L1 degrader), MSETC (SETDB1 inhibitor), and EVT801 (VEGFR3 inhibitor) pipeline assets. We project approximately $500M in peak paxalisib sales predominantly in TNBC and initiate at BUY with a $34 price target. "

For an analyst ratings summary and ratings history on Kazia Therapeutics click

BTIG Starts Kazia Therapeutics (KZIA) at Buy

Wed, 01 Jul 2026 06:06:30 -0400

BTIG analyst Kambiz Yazdi initiates coverage on Kazia Therapeutics (NASDAQ: KZIA) with a Buy rating and a price target of $34.00.

For an analyst ratings summary and ratings history on Kazia Therapeutics click

Form 4 KAZIA THERAPEUTICS LTD For: Jun 19 Filed by: Rao Sudha

Tue, 23 Jun 2026 18:47:00 -0400

si-local-file:///var/storage/secattach/20260623/26680904.html

Form 4 KAZIA THERAPEUTICS LTD For: Jun 19 Filed by: Rao Sudha

Tue, 23 Jun 2026 18:47:00 -0400

si-local-file:///var/storage/secattach/20260623/26680904.html

Form 4 KAZIA THERAPEUTICS LTD For: Jun 19 Filed by: Levine James E.

Tue, 23 Jun 2026 18:47:00 -0400

si-local-file:///var/storage/secattach/20260623/26680905.html

Form 4 KAZIA THERAPEUTICS LTD For: Jun 19 Filed by: Levine James E.

Tue, 23 Jun 2026 18:47:00 -0400

si-local-file:///var/storage/secattach/20260623/26680905.html

Form 3 KAZIA THERAPEUTICS LTD For: Jun 01 Filed by: Levine James E.

Mon, 15 Jun 2026 18:53:00 -0400

si-local-file:///var/storage/secattach/20260615/26648958.html

Form 3 KAZIA THERAPEUTICS LTD For: Jun 01 Filed by: Levine James E.

Mon, 15 Jun 2026 18:53:00 -0400

si-local-file:///var/storage/secattach/20260615/26648958.html

Lake Street Starts Kazia Therapeutics (KZIA) at Buy

Thu, 11 Jun 2026 08:12:46 -0400

Lake Street initiates coverage on Kazia Therapeutics (NASDAQ: KZIA) with a Buy rating and a price target of $32.00.

For an analyst ratings summary and ratings history on Kazia Therapeutics click here. For more ratings news on Kazia Therapeutics click here.

Shares of Kazia Therapeutics closed at $11.50 yesterday.

Form 3 KAZIA THERAPEUTICS LTD For: Mar 18 Filed by: Davidson Ebru

Wed, 03 Jun 2026 20:20:00 -0400

si-local-file:///var/storage/secattach/20260603/26601041.html

Form 3 KAZIA THERAPEUTICS LTD For: Mar 18 Filed by: Davidson Ebru

Wed, 03 Jun 2026 20:20:00 -0400

si-local-file:///var/storage/secattach/20260603/26601041.html

The Multi-Billion-Dollar Search for Better Glioblastoma Treatments

Wed, 03 Jun 2026 09:28:24 -0400

Why Investors Continue Watching One of Oncology's Most Difficult Frontiers

DENVER, June 03, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Cancer treatment has advanced dramatically over the past two decades. Precision medicine, immunotherapy, antibody-drug conjugates, and targeted therapies have transformed outcomes for patients across multiple tumor types.

Yet one of oncology's greatest challenges remains largely unsolved.

Glioblastoma.

Despite billions of dollars invested in research and development, glioblastoma remains one of the deadliest forms of cancer, with patients often facing limited treatment options and poor long-term survival rates. The disease's aggressive nature, combined with

The Multi-Billion-Dollar Search for Better Glioblastoma Treatments

Wed, 03 Jun 2026 09:28:24 -0400

Why Investors Continue Watching One of Oncology's Most Difficult Frontiers

Yet one of oncology's greatest challenges remains largely unsolved.

Glioblastoma.